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Reactive oxygen species (ROS) and signaling events are involved in the pathogenesis of
endothelial dysfunction and represent a major contribution to vascular regulation. Molecu-
lar signaling is highly dependent on ROS. But depending on the amount of ROS production
it might have toxic or protective effects. Despite a large number of negative outcomes in
large clinical trials (e.g., HOPE, HOPE-TOO), antioxidant molecules and agents are impor-
tant players to inﬂuence the critical balance between production and elimination of reactive
oxygen and nitrogen species. However, chronic systemic antioxidant therapy lacks clinical
efﬁcacy, probably by interfering with important physiological redox signaling pathways.
Therefore, it may be a much more promising attempt to induce intrinsic antioxidant path-
ways in order to increase the antioxidants not systemically but at the place of oxidative
stress and complications. Among others, heme oxygenase (HO) has been shown to be
important for attenuating the overall production of ROS in a broad range of disease states
through its ability to degrade heme and to produce carbonmonoxide and biliverdin/bilirubin.
With the present review we would like to highlight the important antioxidant role of the
HO system and especially discuss the contribution of the biliverdin, bilirubin, and biliverdin
reductase (BVR) to these beneﬁcial effects.The BVR was reported to confer an antioxidant
redox ampliﬁcation cycle by which low, physiological bilirubin concentrations confer potent
antioxidant protection via recycling of biliverdin from oxidized bilirubin by the BVR, linking
this sink for oxidants to the NADPH pool. To date the existence and role of this antioxidant
redox cycle is still under debate and we present and discuss the pros and cons as well as
our own ﬁndings on this topic.
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INTRODUCTION
The endothelial integrity is crucial for physiologic organ function
and protects against vascular inﬂammation, sepsis, prothrombotic
Abbreviations: 2-HE, 2-hydroxyethidium; AAPH, 2,2′-azobis(2-amidinopropane)
hydrochloride; ACE, angiotensin-converting enzyme; ApoE−/−, apolipoprotein E
deﬁciency (knock-out); ARB, angiotensin-receptor blocker; Aβ, amyloid-β peptide;
BH2, dihydrobiopterin; BH4, tetrahydrobiopterin; BR, bilirubin; BSA, bovine serum
albumin; BV, biliverdin; BVR, biliverdin reductase; CAD, coronary artery disease;
CO, carbon monoxide; CORM-2, CO-releasing molecule-2; DHE, dihydroethi-
dine (dihydroethidium); DHR, dihydrorhodamine 123; DMSO, dimethyl sulfoxide;
DNA,deoxyribonucleic acid; ECL,enhanced chemiluminescence; eNOS,endothelial
nitric oxide synthase (NOS-3); GCH-1, GTP-cyclohydrolase-1; GTN, glyceryl trini-
trate (nitroglycerin); HDF, human ﬁbroblast; HPLC, high performance liquid chro-
matography; HO, heme oxygenase; HO-1, heme oxygenase-1 (inducible isoform);
HO-2, heme oxygenase-2 (constitutive isoform); HRP, horseradish peroxidase;
HUVECs,humanumbilical vein endothelial cells;KO2,potassiumsuperoxide; L-012
luminol analog; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase;
MnSOD,manganese superoxide dismutase (SOD2,mitochondrial isoform);mRNA,
messenger ribonucleic acid; NO, nitric oxide (nitrogen monoxide); nNOS, neuronal
nitric oxide synthase (NOS-1); PARP, poly(ADP-ribose)polymerase; PETN, pen-
taerithrityl tetranitrate; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C;
RONS, reactive oxygen and nitrogen species; ROS, reactive oxygen species; RT-PCR,
reverse transcription-polymerase chain reaction; Sin-1,3-morpholino-sydnonimine
(active metabolite of molsidomine); siBVR, small interfering RNA against BVR;
siHO-1, small interfering RNA against HO-1; siRNA, small interfering RNA; TNF-α,
tumor necrosis factor-α; XO, xanthine oxidase.
activity, and atherosclerosis (Bassenge et al., 2005). Disruption of
this blood–tissue (endothelial) barrier results in endothelial dys-
functionwhich is a hallmark of most cardiovascular complications
(Cai and Harrison, 2000; Munzel et al., 2008). Reactive oxygen
species (ROS) and signaling events are involved in the pathogene-
sis of endothelial dysfunction and represent a major contribution
to vascular regulation. ROS are important regulators for cellular
and metabolic conditions. Molecular signaling is highly depen-
dent on ROS. But depending on the amount of ROS production
it might have toxic or protective effects (Bachschmid et al., 2005;
Daiber and Münzel, 2006; Ullrich and Kissner, 2006).
Despite a large number of negative outcomes in large clin-
ical trials (HOPE, HOPE-TOO as well as a prospective study
with vitamin C in postmenopausal women with diabetes melli-
tus; Yusuf et al., 2000; Muntwyler et al., 2002; Lee et al., 2004;
Mann et al., 2004; Lonn et al., 2005), antioxidant molecules and
agents are important players to inﬂuence the critical balance
between production and elimination of reactive oxygen and nitro-
gen species (RONS). The latter assumption is supported by a
great number of experimental animal studies (Watanabe et al.,
1997; Bassenge et al., 1998; Crawford et al., 1998; Elhaimeur
et al., 2002) as well as human studies with rather small num-
bers of patients and acute infusion of antioxidants (Heitzer et al.,
1996; Gori et al., 2001) indicating that antioxidants may be highly
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beneﬁcial in improving endothelial dysfunction. The main rea-
sons for the failure of chronic oral antioxidant therapy could be as
follows: vitamin E and C act as pro-oxidants (e.g., tocopheryl and
ascorbyl radicals), the coronary artery disease (CAD) of included
patients is already irreversible, theCADpatients are already treated
with drugs displaying antioxidant properties [e.g., angiotensin-
converting enzyme (ACE) inhibitors and angiotensin-receptor
blockers (ARBs)], chronic antioxidant therapy inhibits intrinsic
ischemic preconditioning which relies on RONS formation or oral
vitamin treatment does not result in high enough concentrations
of the antioxidants at the place of oxidative stress (Chen et al.,
2012).
Someof these reasonswould favor the acute infusion of vitamin
C in accordance with respective observations. However, infusion
of antioxidants cannot be applied to a large number of patients
over a long period and in addition may be affected by some of
the draw backs listed above under chronic administration (e.g.,
interference with cellular redox signaling, suppression of oxidant-
triggered ischemic preconditioning). Therefore, it may be a much
more promising attempt to induce intrinsic antioxidant pathways
in order to increase the antioxidants not systemically but at the
place of oxidative stress and complications. A number of exper-
imental animal studies have demonstrated that overexpression
of ROS sources aggravates cardiovascular complications, whereas
their suppression improves these adverse effects: the genetic dele-
tion of NADPH oxidase subunits improved myocardial infarction
damage and survival of mice (Doerries et al., 2007) and prevented
angiotensin-II (Landmesser et al., 2002) as well as renovascular
(clip model; Jung et al., 2004) induced hypertension, oxidative
stress, and endothelial dysfunction. In contrast, overexpression
of NADPH oxidase subunits further aggravated these compli-
cations (Dikalova et al., 2005). Vice versa, deletion of the mito-
chondrial manganese superoxide dismutase (MnSOD) increased
age-dependentmitochondrial oxidative stress and endothelial dys-
function (Wenzel et al., 2008a) and deﬁciency in glutathione
peroxidase-1 potentiated atherosclerosis and vascular complica-
tions in ApoE−/− mice (Torzewski et al., 2007). The recent obser-
vation that overexpression of mitochondrial superoxide dismutase
improves angiotensin-II triggered hypertension and vascular dys-
function in mice shows that the different ROS sources can directly
inﬂuence each other (Dikalova et al., 2010) and that especially
the cross-talk between the mitochondrial and NADPH oxidase
redox axis may play an important role for various diseases (Daiber,
2010).
Among others, heme oxygenase (HO) has been shown to be
important for attenuating the overall production of ROS through
its ability to degrade heme and to produce carbon monoxide
(CO), biliverdin/bilirubin, and the release of free iron with subse-
quent ferritin induction (Vitek and Schwertner, 2007; Abraham
and Kappas, 2008). It should be noted that free iron itself is
toxic for the cell and may contribute to cellular oxidative dam-
age (e.g., by reduction of free iron(III) to iron(II) by superoxide
and subsequent reaction of ferrous iron with hydrogen perox-
ide to yield hydroxyl radicals. The latter step is termed “Fenton
reaction,” the overall process is the “Haber–Weiss-cycle” (Daiber
and Münzel, 2006). Therefore, it is of great importance to keep
the free iron levels low, which also includes that induction of
HO is followed by subsequent induction of ferritin. Heme and
P450 overload has been demonstrated to confer cytotoxic effects
(Eipel et al., 2007), which provides a simple basis for the highly
beneﬁcial action of HO consisting of the direct detoxiﬁcation of
free heme. Besides the highly protective effects of heme oxyge-
nase (HO-1) in various pathophysiological states, its down-stream
targets bilirubin and biliverdin have reducing properties and are
recognized as potent antioxidants (Stocker et al., 1987), but it is
not fully understood how the bile pigments act in this molecular
process and the role of biliverdin reductase (BVR) needs to be
further explored. The localization of heme degradation enzymes
(e.g., HO-1 and BVR) to plasma membrane caveolae and evi-
dence on caveolin-1 interaction with HO-1 and modulation of its
activity make the HO-1 system an attractive player in the vascu-
lar antioxidant system since also the redox-sensitive endothelial
nitric oxide synthase (eNOS) as well as superoxide producing
enzymes are located in the plasma membrane caveolae (Kim et al.,
2004).
Heme oxygenase-1 degrades heme to biliverdin, which is then
reduced by BVR to bilirubin. During the last decade BVR has
attracted more attention on the background of an active antioxi-
dant cycle providing a catalytic sink for RONS as well as cytopro-
tection (Baranano et al., 2002; Sedlak and Snyder, 2004). However,
this concept is still under debate with a number of highly contro-
versial reports (Maines, 2007; Pachori et al., 2007; Florczyk et al.,
2008; Maghzal et al., 2009; Sedlak and Snyder, 2009; Young et al.,
2009; Jansen et al., 2010). With the present review we provide an
overview on our own results, the current literature and critically
discuss the pros and cons of the antioxidant and cytoprotective
concept underlying the action of BVR.
THE CONCEPT OF BILIVERDIN REDUCTASE AND OXIDANTS
FORMING A CATALYTIC ANTIOXIDANT CYCLE
In 2002 an attractive concept was put forward by Snyder and
colleagues consisting of the BVR mediated reduction of biliverdin
(BV) to bilirubin (BR) being the much more potent antioxi-
dant and subsequent oxidation of BR by hydrogen peroxide back
to BV forming a catalytic antioxidant cycle that is driven by
NADPH, the reducing cofactor of BVR (see Figure 1; Baranano
et al., 2002; Greenberg, 2002; Sedlak and Snyder, 2004). Especially
lipophilic ROS such as lipid hydroperoxides and peroxyl radicals
were described to feed this antioxidant cycle and later, synergistic
effects of glutathione have been described (Sedlak et al., 2009). In
their initial work, Baranano et al. demonstrated that BR (10 nM)
increased the viability of HeLa cells in the presence of toxic concen-
trations of hydrogen peroxide (100 μM). The fact that 10,000-fold
lower BR concentrations prevented the toxicity of H2O2 implied
that there was some kind of “recycling” of BR resulting in the
proposed BV/BR redox cycle. In addition, small interfering RNA
(siRNA) against BVR resulted in higher ROS levels in HeLa cells
and neurons, decreased the viability of neurons upon treatment
with H2O2, increased caspase activity and apoptosis [envisaged
by poly(ADP-ribose)polymerase (PARP) activation] in these cells.
In response to the review article of Sedlak and Snyder, Antony
McDonagh (1990), a pioneer on the bile pigment ﬁeld, questioned
the importance of the oxidative conversion of BR to BV since
BR radicals are also reduced in a non-enzymatic environment by
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FIGURE 1 | Hypothetical scheme of the antioxidant redox cycle of the
BR/BV/BVR system. Modiﬁed from Sedlak and Snyder (2004).
interaction with molecular oxygen – these considerations were
published in a letter to the editor (McDonagh, 2004). In addition,
Antony McDonagh pointed out that there is only marginal con-
version of BR to BV under special conditions and generation of
certain oxidants, which was supported by our observations using
superoxide, peroxynitrite, hydrogen peroxide, and peroxidase sys-
tems (see chapter below).These reports stimulatedus to investigate
this potential sink for RONS in vitro (chemicalmodels) and ex vivo
(human endothelial cells).
OWN RESULTS
DIRECT ANTIOXIDANT PROPERTIES OF BILIRUBIN VERSUS BILIVERDIN
IN VITRO
As shown by Jansen et al. (2010) bilirubin represents a superior
antioxidant as compared to biliverdin when applied in high con-
centrations. Using cell-free systems (test tube chemistry) the direct
antioxidant effects of bilirubin versus biliverdin were assessed.
The peroxynitrite scavenging ability of both bile pigments was
assessed by two different biochemical models: tyrosine residues
in bovine serum albumin (BSA) were either nitrated by authen-
tic peroxynitrite (ONOO−) or in situ generated ONOO− from
the thermal decomposition of 3-morpholino-sydnonimine (Sin-
1), a more physiological model to assess peroxynitrite-mediated
oxidations. Peroxynitrite-mediated tyrosine nitration involves
tyrosyl-radical-intermediates as a consequence of homolytic bond
cleavage in ONO-OH yielding hydroxyl (HO•) and nitrogen
dioxide (•NO2) radicals. Therefore, inhibition of peroxynitrite-
mediated BSA nitration may be regarded as ability of BR and BV
to scavenge peroxynitrite-derived free radicals and/or reduction
of tyrosyl-radical-intermediates. According to our results, BR is at
least threefold more potent than BV in inhibiting peroxynitrite-
mediated protein tyrosine nitration. The used dot blot tech-
nique excludes any interference of the BR or BV color since the
compounds are removed during transfer of the sample to the
membrane.
Superoxide scavenging ability of BR and BV was determined in
two different systems. In the ﬁrst one superoxide was constantly
generated by xanthine oxidase (XO) and hypoxanthine whereas
in the second one we used authentic superoxide (KO2) to exclude
any inhibitory effects of the compounds on enzymatic activity
(e.g., one of the compounds could be an inhibitor of XO). Since
the color of BR and BV may lead to false-positive results using
direct optical methods, we used HPLC-based detection of ﬂuo-
rescent 2-hydroxyethidium (2-HE), the speciﬁc oxidation product
of dihydroethidium and superoxide. XO-derived superoxide was
decreased in a concentration-dependent fashion by BR whereas
BV had no inhibitory effect and even signiﬁcantly increased the
signal pointing toward pro-oxidative effects. It should be noted
that the absolute increase in superoxide signal by BV was small
(approximately 10%). Using KO2 from a saturated stock solution
in dimethyl sulfoxide (DMSO), the above described differences
even became more pronounced: BR decreased the formation of 2-
hydroxyethidium in a concentration-dependent fashion whereas
BV, this time, dramatically increased its yield up to 2.5-fold over
KO2 control without BR or BV. This may be taken as evidence
for redox-cycling of BV amplifying the superoxide formation rate.
Again, the used HPLC technique excludes any interference of the
BR or BV color since the compounds are separated from the
product during their way through the column.
NO EVIDENCE FOR CONVERSION OF BILIRUBIN TO BILIVERDIN BY
DIFFERENT OXIDANTS IN VITRO
Bilirubin or BV (each 50 μM) were incubated with authentic per-
oxynitrite, Sin-1, KO2, hydrogen peroxide alone or together with
horseradish peroxidase (HRP). The latter would generate per-
oxidase compound I, having hydroxyl radical-like, one-electron
abstracting properties. There was a pronounced loss of BR in all
systems used indicating that BR reacted with any reactive species
formed. In contrast, BV was converted less efﬁciently (not at all
by superoxide), only the peroxidase/H2O2 system completely con-
sumedBV. Special emphasis was put on the conversion of BR toBV
by the different oxidants, the process that was previously described
by Snyder and coworkers (Baranano et al., 2002; Sedlak andSnyder,
2004). However, we were unable to detect any signiﬁcant conver-
sion of BR to BV questioning the role of BR/BV as catalysts in the
break-down of RONS. We also observed no conversion of BR to
BV by mitochondrial oxidative stress but also no signiﬁcant con-
version of BV to BR by intrinsic mitochondrial BVR. Also here, we
strictly used an HPLC technique excluding any interference of the
BR or BV color since the compounds are separated during their
way through the column.
(IN)DIRECT ANTIOXIDANT PROPERTIES OF BILIRUBIN VERSUS
BILIVERDIN EX VIVO
Efﬁcacy of BR and BV as antioxidants was also tested in isolated
heart mitochondria (see Figure 2). Mitochondrial respiratory
chain was stimulated with succinate and blocked by the complex
III inhibitor antimycinA,whichdirectsROS toward the intermem-
brane space. ROS and RNS formation was detected by the luminol
analog L-012 enhanced chemiluminescence (ECL) detecting intra-
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FIGURE 2 | Effects of BR and BV on mitochondrial oxidative stress.
Adopted from Jansen et al. (2010). With permission of Rightslink® by
Copyright Clearance Center (Elsevier).
and extra-mitochondrial reactive species. BR sensitively decreased
the L-012 signal at submicromolar concentrations being threefold
more efﬁcient as compared to BV. In contrast, suppression of the
intra-mitochondrial superoxide formation, that was measured by
the yield of 2-hydroxyethidium, required 1000-fold higher con-
centrations of BR and the difference between BR and BV was less
pronounced.
The inhibitory effects of BR and BV on oxidative burst in
phorbol ester-stimulated neutrophils was detected by L-012 ECL
indicating less pronounced differences between BR and BV, as
compared to mitochondria. BR and BV decreased the signal in
a concentration-dependent fashion but BR was only marginally
more potent than BV. The less pronounced difference may be
due to the involvement of myeloperoxidase/H2O2 in the signal
intensity. The reactivity of BR and BV may be very similar for
the reactive species derived from the peroxidase/H2O2 system
in accordance with the almost identical break-down pattern of
BR and BV caused by HRP/H2O2 (see third paragraph in the
preceeding chapter). However, the superoxide-speciﬁc product 2-
hydroxyethidium revealed a more pronounced antioxidative effect
of BR as compared to BV, which even caused a marginal increase
in the signal. Regarding the weak differences between BR and BV
in the chemiluminescence assay it should be taken into account
that the color of the bile pigments may have interfered with the
ECL signal. Therefore, the HPLC data may be more reliable.
ANTIOXIDANT PROPERTIES OF THE HEME OXYGENASE SYSTEM AND
EFFECTS OF BILIVERDIN REDUCTASE SILENCING IN HUMAN
ENDOTHELIAL CELLS
Knock-out models by genetic gene deletion are useful tools to
investigate enzyme and protein functions. Until now, BVR knock-
outmicedonot exist and inhibitors are not commercially available.
Therefore, silencing of the BVR gene by siRNA is often used as
molecular method in most experiments. We investigated BVR
silencing in humanumbilical vein endothelial cells (HUVECs) and
observed signiﬁcant effects in resting cells without oxidative stim-
ulus characterized by an increase in intracellular oxidative stress
(measured by intracellular 2-HE formation). With lipopolysac-
charide (LPS)-elicited RONS formation we established a model
for cellular oxidative stress in HUVECs and endothelial cell acti-
vation,which reﬂects endotoxin-triggered endothelial dysfunction
and may be used as a clinical model for septic shock.
Treatment of HUVECs with siBVR or siHO-1 resulted in a
>90% decrease at the messenger ribonucleic acid (mRNA) level
which was measured by reverse transcription-polymerase chain
reaction (RT-PCR) and envisaged on agarose gels. Basal superox-
ide levels in these cells were determined by 2-hydroxyethidium
formation, which was signiﬁcantly increased in BVR-silenced
cells. After characterization of the ideal conditions for cellular
oxidative stress and protection by HO-1 induction these ﬁnd-
ings were applied to BVR and HO-1-silenced HUVECs. Hemin
decreased the LPS-triggered oxidative stress [dihydrorhodamine
123 (DHR) ﬂuorescence] in control cells whereas this protective
effect was almost lost in BVR-deﬁcient cells and completely absent
in HO-1-depleted cells. When the BVR substrate BV was added
to lipopolysaccharide-stimulated HUVECs the decrease in DHR
ﬂuorescence in control cells was more pronounced at a percentage
level as compared to BVR-silenced cells (20.1 versus 15.4%).
These ﬁndings were supported by a second parameter for
oxidative stress, protein tyrosine nitration. 3-nitrotyrosine stain-
ing even revealed a more pronounced effect of BVR and HO-1
silencing. In LPS-stimulated HUVECs hemin caused a decrease
in 3-nitrotyrosine staining at 3.3 and 10μM whereas nitration
was signiﬁcantly increased in BVR- and HO-1-deﬁcient cells and
the protective effect of hemin was completely lost. In addition,
the substrate for BR synthesis by BVR decreased the level of
3-nitrotyrosine- positive proteins in a concentration-dependent
fashion in control cells whereas this protective effect of BV was lost
in BVR-silenced cells. The highest concentration of BV (10μM)
even tended to increase the nitration instead of preventing it, sup-
porting the observed redox-cycling by BV (see second paragraph
in the preceeding chapter). Treatment of HUVECs with siBVR or
siHO-1 resulted in a >80% or complete decrease at the protein
level which was measured by Western blotting.
A last set of experiments aimed to demonstrate the impor-
tance of chronic indirect effects of the HO-1/BVR product BR.
LPS treatment of an immortal endothelial cell line (EA.hy 926
cells) decreased the expression of the tetrahydrobiopterin (BH4)
synthase GTP-cyclohydrolase-1 (GCH-1). BV had no effect on
endothelial expression of this important enzyme whereas BR as
well as the CO-releasing molecule-2 (CORM-2) derived CO dra-
matically increased the GCH-1 protein levels. It should be noted
that BH4 levels are crucial for the function of eNOS and BH4
deﬁciency leads to uncoupling of eNOS and subsequent forma-
tion of RONS. Therefore prevention of GCH-1 down-regulation
or degradation may represent an important antioxidant path-
way. Previous reports have demonstrated that oxidative stress may
trigger the proteasomal degradation of GCH-1 (Xu et al., 2007,
2009). Especially for the endothelium it may be crucial to main-
tain the BH4 levels under conditions of increased oxidative stress
to prevent eNOS uncoupling and endothelial dysfunction. Inter-
estingly, the levels of the dihydrobiopterin (BH2) recycling enzyme
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dihydrofolate reductase behave complementary to those of GCH-
1 in accordance with our previous results in diabetic rats (Wenzel
et al., 2008b; Oelze et al., 2011).
OTHER REPORTS IN FAVOR OF AN IMPORTANT ROLE OF
BILIVERDIN REDUCTASE FOR ANTIOXIDANT AND
CYTOPROTECTIVE EFFECTS OF THE HEME OXYGENASE
SYSTEM
Previous reports suggested an efﬁcient catalytic cycle between
BV and BR (Baranano et al., 2002; Sedlak and Snyder, 2004;
Liu et al., 2006) and others have observed conversion of BR
to BV by peroxynitrite (Kaur et al., 2003), or peroxyl radi-
cals (Baranano et al., 2002). In support of these previous ﬁnd-
ings and a role of BVR in cytoprotection, Young et al. (2009)
demonstrated that angiotensin-II induced superoxide formation
in renal tubular epithelial cells and inner medullary collecting
duct (IMCD3) cells is aggravated by silencing of BVR. Superox-
ide formation was measured using dihydroethidine (DHE) ﬂuo-
rescence and lucigenin-derived chemiluminescence. BVR silenc-
ing resulted in a signiﬁcantly decreased level of BVR protein
(>30% of control cells) as well as diminished cellular biliru-
bin concentrations (50% of control cells). Co-treatment with
BV could decrease the angiotensin-II induced superoxide for-
mation in control cells, whereas it further aggravated the ROS
levels in BVR-silenced cells. This is in good accordance with
our observations on increased superoxide levels by biliverdin
in the presence of xanthine oxidase or authentic superoxide,
most probably via redox-cycling (see the preceeding chapter).
However, it should be noted that Young et al. also observed
BVR/BR independent antioxidant action of HO-1, since hemin
co-treatment improved superoxide formation in BVR-silenced
cells, indicating an important contribution of CO (and other so
far not identiﬁed routes). The beneﬁcial effect of hemin could
of course also be related to increased break-down of superoxide
in the presence of hemin leading to other reactive intermediates
or non-toxic products that are not detected by DHE ﬂuores-
cence. Of note, we have observed a more pronounced burden
of oxidative stress in endothelial cells treated with HO-1 siRNA
as compared to BVR siRNA suggesting on top protective path-
ways mediated by HO-1 activation (most probably CO formation)
as compared with the BVR pathway alone (see the preceeding
chapter).
Another previous report by Liu et al. (2006) demonstrated
increased cellular oxidative stress in BVR-deﬁcient cells using a
model of experimental autoimmune encephalomyelitis. In detail,
BVR treatment of encephalomyelitic rats improved the tissue lev-
els of 8-isoprostane in the spinal cord but also the clinical score of
the disease (50% for BVR and 66% for HO-1 of encephalomyelitic
rats). In isolated cells, BVR silencing had much more pronounced
effects on increase in ROS levels and decrease in cell viability as
compared to HO-1 inhibition by Sn-pophyrin. The down-stream
product of BVR, BR, showed a much more pronounced effect on
erythrocyte hemolysis by the complement in the classical path-
way and lymphocyte activity (antibody-dependent cell-mediated
cytotoxic activities) as compared to the antioxidant glutathione.
However, since HO-1 treatment or inhibition displayed weaker
effects as compared to BVR treatment or silencing, the data of this
study rather point to an effect of BVR that is independent of the
antioxidant action of BR.
Panahian et al. (1999) reported on enhanced neuronal expres-
sion of BVR after permanent focal cerebral ischemia and spec-
ulated that this may be a new cellular mechanism for protect-
ing neurons against ischemic injury and oxidative stress. Cere-
bral ischemia was induced by permanent middle cerebral artery
occlusion and increased BVR expression obviously contributed to
increased survival of neurons in the peri-ischemic region. Pre-
vious reports introduced an additional function for BVR. The
protein contains a region with a leucine zipper deoxyribonucleic
acid (DNA)-binding motif and binds as a homodimer to a region
of the HO-1 promoter that contains two AP-1 sites (Ahmad et al.,
2002). By this action BVR may prevent cellular damage not only by
catalyzing the formation of the antioxidant bilirubin, but also by
transcriptional activation of HO-1 triggering the efﬂux of poten-
tially toxic iron from cells exposed to oxidative stress (Baranano
and Snyder, 2001). The latter observation was also shared by us
since BVR silencing also partially decreased HO-1 protein levels,
whichmay be related to a role of BVR for transcriptional activation
of HO-1 (Jansen and Daiber, unpublished).
Finally, it was shown by Maines and coworkers that BVR with-
out any action of BR may change the cellular antioxidant proﬁle by
regulation of protein kinase C (PKC-βII) activity (Maines, 2007;
Maines et al., 2007), which may represent an important BVR-
dependent protective pathway based on PKC-ζ under inﬂamma-
tory conditions [e.g., tumor necrosis factor-α (TNF-α) signaling;
Lerner-Marmarosh et al., 2007]. This pathway involves insulin
receptor 1/2 signaling, the insulin/growth factor signaling cascade
for protein/ DNA synthesis and glucose transport down-stream of
mitogen-activated protein kinase (MAPK) and phosphatidylinos-
itol 3-kinase (PI3K). This kinase activity of BVR provides a great
link between heme metabolism and cell signaling. Further down-
stream in this signaling cascade, BVR may also directly interact
with the transcription factors ATF-2/CREB, c-fos, c-jun prevent-
ing apoptosis. Even protective actions of BVR on arsenite toxicity
were described that were completely independent and not shared
by HO-1 (Miralem et al., 2005).
There is also further wide-spread evidence for beneﬁcial effects
of BVR in various disease models. In a model of oxidative dam-
age in maternal cholestasis during pregnancy, upregulation of
BVR was suggested to confer protection of the placental–fetal unit
since the viability of human choriocarcinoma JAr cells was signiﬁ-
cantly increasedbybilirubin in a concentration-dependent fashion
(Perez et al., 2008). Another report demonstrated that the antioxi-
dants biliverdin/bilirubin might play an important role in the pro-
tection of the nitrergic neurotransmitter against oxidative stress
in murine gastric fundus (De Backer and Lefebvre, 2008). The
authors demonstrated, that neurotransmission (neuronal nitric
oxide synthase, nNOS-dependent relaxation in murine jejunal
circular smooth muscle strips) was impaired by the superoxide
generator LY83583, a process that was prevented by BR and to a
smaller extend by BV but not by CO. From these observations and
the colocalization of HO-2 and BVR with nNOS they concluded
that the BR pathway but not the CO pathway down-stream of
heme oxygenase-2 (HO-2) confer antioxidant protection of the
neurotransmission process in the gastric fundus although this
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protective action was not observed under normal physiological
conditions but only in response to oxidant challenges. In a model
of cell senescence, Kim et al. (2011) found a striking decrease in
BVR expression in senescent human ﬁbroblasts (HDF cells) as
compared to young HDF cells. Vice versa, senescent ﬁbroblasts
had signiﬁcantly increased ROS levels in comparison with young
HDF cells, a difference that was eliminated by BVR siRNA treat-
ment suggesting a role of BVR in the young ﬁbroblasts in the
detoxiﬁcation of ROS. Hydrogen peroxide caused an appreciable
induction of HO-1 in the young ﬁbroblasts (with high expres-
sion of BVR) whereas this antioxidant response was absent in the
senescent HDF cells (with low BVR expression). Again, this dif-
ferential stress response was eliminated when siRNA treatment
against BVR was applied. As a functional read-out, the depletion
of BVR isoformA could reduce the cell number by>60% in young
HDFs even without additive exogenous oxidative stress, a process
that was accompanied by increased expression of the expression of
the senescence marker SA-β-gal. A recent study demonstrated that
BV rescues the HO-2 knock-out mouse phenotype of unresolved
chronic inﬂammation following corneal epithelial injury and the
authors suggested a beneﬁcial role of the upregulated BVR in this
model (Bellner et al., 2011).
OTHER REPORTS NOT IN FAVOR OF AN IMPORTANT ROLE OF
BILIVERDIN REDUCTASE FOR ANTIOXIDANT AND
CYTOPROTECTIVE ACTIONS OF THE HEME OXYGENASE
SYSTEM
According to a recent publication of Maghzal et al. (2009) revis-
iting the previous ﬁndings of Snyder and colleagues neither BVR
overexpression nor silencing changed hydrogen peroxide toxicity
inHeLa cells, an immortal human cancer cell line. In detail, Stocker
and coworkers could show that lipid peroxidation-mediated oxi-
dation of BR in chloroform, did not yield BV (see similar observa-
tions by us, preceeding chapters). Similarly, H2O2 did not oxidize
albumin-bound BR to BV, and only modest yields of BV were
observed upon in vitro oxidation of albumin- or ligandin-bound
BR in the presence of peroxyl radicals. The viability of HeLa cells
wasnot decreased in thepresenceof hydrogenperoxide after deple-
tion of cellular BVR protein and activity in vitro using siRNA
against BVR.Vice versa BVR overexpression failed to enhance pro-
tection of HeLa cells against H2O2-mediated damage, irregardless
of whether BR or BV were added to the cells as substrate for the
putative redox cycle. The authors also showed that overexpres-
sion of human BVR in HeLa cells did not decrease H2O2-induced
ROS levels. Finally, they highlighted that HO-1 overexpression but
not BVR overexpression rescued cell survival of HeLa cells in the
presence of hydrogen peroxide. In a letter to the editor, Snyder
and colleagues criticized the experimental setup in the work of
Maghzal et al. with special emphasis on the need for providing
BV by either exogenous addition or endogenous activation of the
HO-1 system (Sedlak and Snyder, 2009), as done in our cell culture
experiments (see preceeding chapters). In addition, these authors
criticized the high hydrogen peroxide concentrations employed by
Stocker and coworkers as well as the time point at which cell death
and ROS measurements were detected (4–8 h) in contrast to the
maximum protection observed by BVR at 24 h. In the direct reply
letter to the editor, Stocker and Maghzal pointed out that previous
work supporting a role for BVR in cytoprotection and antioxidant
effects (e.g., Miralem et al., 2005; Maines, 2007) provided beneﬁ-
cial data that was largely independent of the presence of BR and
the reductase activity of BVR and were therefore not in support
of the antioxidant BV/BR/BVR redox cycle (Stocker and Maghzal,
2009). Even more important, these authors emphasized that BVR
depletion also failed to affect the death of cells loaded with BV or
BR prior to exposure to a 40-fold molar excess of H2O2 (Maghzal
et al., 2009), whereas Snyder and associates reported BR to be able
to defend against a 10,000-fold excess of H2O2 (Baranano et al.,
2002).
In his recent study, Anthony McDonagh demonstrated that
the peroxyl radical generator 2,2′-azobis(2-amidinopropane)
hydrochloride (AAPH) did not result in the formation of BV
from BR in air-saturated solution in the absence of serum albu-
min (McDonagh, 2010). He even observed consumption of BV
under the same conditions arguing against an accumulation of
BV under cellular conditions in the presence of peroxyl radical
formation. In contrast, he described marginal BV formation from
BR in the presence of serum albumin and air-saturated solution,
which was even present in oxygen-free (argon ﬂushed) solutions,
whereas oxygen-saturation eliminated the conversion of BR to BV.
This clearly pointed against a peroxyl-driven conversion of BR to
BV since peroxyl radical generation from AAPH requires oxygen
and most pronounced BR to BV conversion was observed in the
absence of oxygen and required the presence of serum albumin.
Therefore, Anthony McDonagh proposed that secondary protein
radicals formed by the interaction of AAPH with serum albu-
min rather account for the conversion of BR to BV than peroxyl
radicals, suggested to be the converting species by Snyder and
colleagues.
OUTLOOK AND THERAPEUTIC IMPLICATIONS
ANTIOXIDANT AND CYTOPROTECTIVE ROLE OF BVR BUT EVIDENCE
AGAINST THE BV/BR/BVR REDOX CYCLE
The data presented in our previous published work (Jansen et al.,
2010) support the concept that BR is a more potent antioxidant
than BV, but also provide evidence that direct and indirect antioxi-
dant effects of the bile pigments contribute to the beneﬁcial proﬁle
of the HO-1 pathway (e.g., GCH-1 in EA.hy cells; see Figure 3 for
summary). Despite our observations that at high concentrations
of the bile pigments scavenging of RONS is more (peroxynitrite or
superoxide) or less (H2O2 or H2O2/peroxidase) pronounced and
that BV undergoes redox-cycling in the presence of superoxide,
we could not establish an important role for an antioxidant cycle
based on oxidative conversion of BR to BV and reductive reversal
by BVR. The antioxidant effects of BV and BR are concentration-
dependent. About 10μM BR reﬂect the physiological situation
of endothelial cells, which are in direct contact with the blood
stream. The model used by Jansen et al. for cellular oxidative
stress is based on LPS-elicited RONS formation in HUVECs,
which reﬂects endotoxin-triggered endothelial dysfunction and
may be used as a cellular model for septic shock. In this respect,
identiﬁcation of BVR as an important constituent of the antiox-
idant defense system in human endothelial cells has important
implications for the prevention of endothelial dysfunction in car-
diovascular diseases that are associated with increased oxidative
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FIGURE 3 | Scheme summarizing the protective routes in the heme
oxygenase-1 system.Treatment of HUVECs with oxidative stimuli (e.g., LPS)
results in induction of HO-1 which catalyzes the break-down of
metallo-porphyrins to CO (hypoxia-like pathway) or biliverdin. Biliverdin is
further converted by biliverdin reductase (BVR) yielding the potent antioxidant
bilirubin. siRNA against HO-1 blocks induction of HO-1. Hemin is a potent
inducer of HO-1 but also a substrate for it resulting in increased CO and BR
formation. Biliverdin is the substrate of BVR leading to an increase in BR.
siRNA against BVR impairs the conversion of BV to BR. Previous reports
speculated on a catalytic cycle of BV to BR conversion by BVR and
subsequent oxidation of BR to BV by ROS. Adopted from Jansen et al. (2010).
With permission of Rightslink® by Copyright Clearance Center (Elsevier).
stress or chronic inﬂammatory conditions. HO-1 silencing had
more pronounced effects on oxidative stress than BVR deletion
and accordingly HO-1 dependent protection involves other (CO-
or ferritin-dependent) pathways besides the formation of BR or
presence of BVR. Most probably, BR (and/or BVR) and CO act
synergistically in conferring antioxidant protection of endothelial
cells. The antioxidant effects of CO in this synergistic action are
not based on direct RONS scavenging but rather on regulation
of NADPH oxidase activity, P450 activity and induction, opening
of potassium channels, angiogenesis, activation of soluble guany-
lyl cyclase, angiogenesis, interference with MAPK signaling, and
many more (Abraham and Kappas, 2008). The antioxidant effects
of BR in this synergistic action are partially based on direct RONS
scavenging but also on regulation of NADPH oxidase activity,
neutrophil adhesion and inﬂammatory pathways (Abraham and
Kappas, 2008) as well as control of redox sensitive protein lev-
els (e.g., GCH-1; Jansen et al., 2010; Schuhmacher et al., 2011).
Since BV, in our hands, displayed redox-cycling under certain
conditions, we speculate that removal of BV may be even more
important than the formation of BR – or at least both processes
contribute to the antioxidant role of BVR.
According to a recent publication of Maghzal et al. (2009)
revisiting the previous ﬁndings of Snyder and colleagues nei-
ther BVR overexpression nor silencing changed hydrogen per-
oxide toxicity in vitro. Also these authors did not observe any
signiﬁcant oxidative conversion of BR to BV by hydrogen per-
oxide and only modest BV formation from BR in a chemical
model of lipid peroxidation in chloroform or by peroxyl radi-
cals. Whereas the latter observation is in good agreement with
our present ﬁndings since we also did not observe signiﬁcant
conversion of BR by various oxidants or mitochondrial ROS,
we disagree with the conclusion that BR and BVR have no cru-
cial effect on antioxidant protection conferred by HO-1 under
cellular conditions. We think that hydrogen peroxide is an unfor-
tunate model to disproof a role for BVR/BR since we here show
that hydrogen peroxide has only minor reactivity toward BR and
BVR knock-down resulted in increased cellular oxidative dam-
age in a septic shock model based on LPS-triggered peroxynitrite
formation in HUVECs. These considerations are supported by
ﬁndings of Young et al. (2009) demonstrating that angiotensin-II
induced oxidative damage in renal tubular epithelial cells is aggra-
vated by silencing of BVR. These authors also observed BVR/BR
independent antioxidant action of HO-1 indicating an important
contribution of CO and/or BV as well. In a letter to the editor, Sny-
der and colleagues criticized the experimental setup in the work
of Maghzal et al. with special emphasis on the need for providing
BV by either exogenous addition or endogenous activation of the
HO-1 system (Sedlak and Snyder, 2009), as done in our cell culture
experiments.
THERAPEUTIC POTENTIAL OF BVR IN ORGANIC NITRATE TOLERANCE
AND OTHER NEUROLOGICAL/CARDIOVASCULAR COMPLICATIONS
Regarding the therapeutic use of modulatingBVRactivity, itwould
be interesting whether BVR deﬁciency would aggravate organic
nitrate induced vascular damage characterized by endothelial
dysfunction and nitrate tolerance. Vice versa, it would be of
clinical importance whether BVR overexpression may improve
the adverse effects of chronic organic nitrate therapy. During
the past years we were able to demonstrate that HO-1 induc-
tion by hemin was able to prevent nitroglycerin (GTN) induced
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vascular dysfunction and oxidative stress, whereas suppression
of HO-1 activity by apigenin induced a tolerance-like effect in
rats under pentaerithrityl tetranitrate (PETN) therapy (Wenzel
et al., 2007). Previous reports demonstrated that PETN ther-
apy is devoid of nitrate tolerance, endothelial dysfunction, and
oxidative stress (Jurt et al., 2001; Gori et al., 2003; Schnorbus
et al., 2010) and that this beneﬁcial proﬁle is at least partially
based on the induction of HO-1 (Oberle et al., 1999, 2002, 2003)
but also on activation of other cardio-protective genes (Pautz
et al., 2009) as well as improvement of endothelial progenitor
cell function (Thum et al., 2007). Recently, we have demonstrated
that the beneﬁcial proﬁle of PETN is lost in HO-1 deﬁcient
mice and PETN therapy results in induction of nitrate toler-
ance as well as vascular oxidative stress (Schuhmacher et al.,
2010). In a subsequent study we have identiﬁed the transcrip-
tion factor Nrf2 as an important mediator of PETN-dependent
HO-1 induction since cells with silenced Nrf2 did not show
increased HO-1 promoter activity in response to PETN treat-
ment anymore (Schuhmacher et al., 2011). Finally, BR caused a
concentration-dependent decrease in nitroglycerin-inducedmito-
chondrial RONS formation (Wenzel et al., 2007) suggesting that
this powerful antioxidant may contribute to the prevention of
adverse side-effects under chronic PETN therapy by eliminating
toxic RONS species. Since our previous ﬁndings have revealed a
dramatic increase in peroxynitrite (Daiber et al., 2005a,b), associ-
ated with enhanced protein tyrosine nitration (Warnholtz et al.,
2002; Schuhmacher et al., 2009) and loss of function of prosta-
cyclin synthase (Hink et al., 2003) under chronic nitroglycerin
therapy, it may be speculated that the potent RONS (namely
peroxynitrite) scavenging properties of bilirubin (Minetti et al.,
1998; Kaur et al., 2003) contribute to the suppression of nitrate
tolerance by HO-1 induction. Therefore, it would be of great
clinical importance to test the effect of BVR silencing or phar-
macological inhibition and vice versa investigate the effect of
BVR overexpression or pharmacological induction/activation on
chronic outcome of PETN therapy. This would help to clarify
whether the conversion of BV to BR by BVR does signiﬁcantly
contribute to the beneﬁcial proﬁle of HO-1 inductionunder PETN
therapy.
Recent reports propose a link between BVR and beneﬁcial
effects of statins in neurodegenerative disorders such as Alzheimer
disease (Barone et al., 2012; Schneider and Simons, 2012). In detail,
atorvastatin signiﬁcantly increased BVR isoform A protein levels,
phosphorylation and activity only in parietal cortex. Addition-
ally, these authors found signiﬁcant negative correlations between
BVR isoform A and oxidative stress indices, as well as discrimina-
tion learning error scores. Finally, BVR isoform A up-regulation
and post-translational modiﬁcations signiﬁcantly correlated with
β-secretase protein levels in the brain, suggesting a possible role
for BVR isoform A in amyloid-β peptide (Aβ) formation. Preced-
ing work has shown that nitrosative and oxidative stress-induced
modiﬁcations on hippocampal BVR isoform A are an early event
in the pathogenesis of Alzheimer disease (Barone et al., 2011).
The Maines group reported on protection of cardiomyocytes by
synergistic BVR and HO-2 upregulation as a potential strategy
against cardiac dysfunction (Ding et al., 2011). In addition to
these novel observations, a common BVR isoform A polymor-
phism was found to be associated with essential hypertension in
Kazaks (Lin et al., 2011). A recent review by Maines highlights the
beneﬁcial role of BVR in insulin signaling suggesting a therapeutic
potential of BVR in diabetes (Maines, 2011). The unique features
and therapeutic potential of BVR were reviewed by Florczyk et al.
(2008) and the same group also demonstrates that overexpression
of BVR enhances resistance to chemotherapeutics (Florczyk et al.,
2011).
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